Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionIocyte AMI-3 Trial

Faraday Pharmaceuticals, Inc.,announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase III clinical trial assessing the efficacy and safety of FDY-5301 in reducing cardiovascular death and heart failure in anterior ST-segment elevation myocardial infarction patients undergoing primary percutaneous intervention.